Portal de Periódicos da CAPES

S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

2012; Wiley; Volume: 10; Issue: s2 Linguagem: Inglês

10.1111/j.1610-0387.2012.07919.x

1610-0387

Alexander Nast, Wolf‐­Henning Boehncke, Ulrich Mrowietz, H.M. Ockenfels, Sandra Philipp, Kristian Reich, Thomas Rosenbach, Adel Sammain, Martin Schlaeger, Michael Sebastian, Wolfram Sterry, Volker Streit, Matthias Augustin, R. Erdmann, Joachim Klaus, Joachim Koza, S A Muller, Hans‐Dieter Orzechowski, Stefanie Rosumeck, Gerhard Schmid‐Ott, Tobias Weberschock, Berthold Rzany,

Asthma and respiratory diseases

Summary Psoriasis vulgaris is a common and often chronic inflammatory skin disease. The incidence of psoriasis in Western industrialized countries ranges from 1.5% to 2%. Patients afflicted with severe psoriasis vulgaris may experience a significant reduction in quality of life. Despite the large variety of treatment options available, surveys have shown that patients still do not received optimal treatments. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologi sche Gesellschaft (DDG) and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence‐based guidelines for the management of psoriasis. They were first published in 2006 and updated in 2011. The Guidelines focus on induction therapy in cases of mild, moderate and severe plaque‐type psoriasis in adults including systemic therapy, UV therapy and topical therapies. The therapeutic recommendations were developed based on the results of a systematic literature search and were finalized during a consensus meeting using structured consensus methods (nominal group process).